Gina Chu

Gina Chu has a diverse work experience in the field of biotherapeutics and medical research. Gina is currently working as a Principal Scientist at Artiva Biotherapeutics since July 2021. Prior to this, they served as a Senior Scientist at Pfizer from December 2019 to July 2021.

Before joining Pfizer, Gina worked at Cedars-Sinai Medical Center in various roles. Gina started as a Graduate Researcher at Georgia State University in 2006 and later became an Assistant Professor, a Project Scientist-Instructor, and a Postdoctoral Fellow at Cedars-Sinai Medical Center. Their responsibilities included the establishment of in vitro expanded circulating tumor cell (CTC) lines and CTC-derived tumor models, as well as the identification and characterization of metastasis-initiating cells. Gina also demonstrated the amplification and convergence of signaling pathways for cancer metastasis and evaluated the inhibitory effects of Cabozantinib in prostate cancer progression.

Additionally, Gina has experience working as a Research Assistant at National Taiwan University Hospital and as a Graduate Researcher at The University of Waikato, Hamilton NZ, where they focused on studying cell signaling in bone metastasis and the effect of inflammatory markers on sepsis, respectively.

Gina Chu holds a Doctor of Philosophy (Ph.D.) degree in Oncology and Cancer Biology from Georgia State University, completed in 2012. Prior to that, they obtained a Bachelor's Degree in Biochemistry from The University of Waikato, which was completed from 2000 to 2005. Gina also holds a Master's Degree in Molecular Cell Biology from The University of Waikato, completed in 2005.